Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian N. Fleming; Morag Hogben; Sheelagh Frame; Steven J. McClue; Simon R. Green

doi:10.1158/1078-0432.CCR-07-4633

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian N. Fleming, Morag Hogben, Sheelagh Frame, Steven J. McClue, Simon R. Green

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

Original language	English
Pages (from-to)	4326-35
Number of pages	10
Journal	Clinical Cancer Research
Volume	14
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-07-4633
Publication status	Published - 1 Jul 2008

Keywords

Animals
Antineoplastic Agents
Cell Line, Tumor
Cyclin D1
Drug Synergism
Female
Gene Expression Regulation, Neoplastic
Humans
Inhibitory Concentration 50
Mice
Models, Biological
Mutation
Neoplasm Transplantation
Purines
Receptor, erbB-2

Access to Document

10.1158/1078-0432.CCR-07-4633

Cite this

@article{5f21076a75494ebea9c57b2ef9281f3c,

title = "Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents",

abstract = "The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.",

keywords = "Animals, Antineoplastic Agents, Cell Line, Tumor, Cyclin D1, Drug Synergism, Female, Gene Expression Regulation, Neoplastic, Humans, Inhibitory Concentration 50, Mice, Models, Biological, Mutation, Neoplasm Transplantation, Purines, Receptor, erbB-2",

author = "Fleming, {Ian N.} and Morag Hogben and Sheelagh Frame and McClue, {Steven J.} and Green, {Simon R.}",

year = "2008",

month = jul,

day = "1",

doi = "10.1158/1078-0432.CCR-07-4633",

language = "English",

volume = "14",

pages = "4326--35",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

AU - Fleming, Ian N.

AU - Hogben, Morag

AU - Frame, Sheelagh

AU - McClue, Steven J.

AU - Green, Simon R.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

AB - The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

KW - Animals

KW - Antineoplastic Agents

KW - Cell Line, Tumor

KW - Cyclin D1

KW - Drug Synergism

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Inhibitory Concentration 50

KW - Mice

KW - Models, Biological

KW - Mutation

KW - Neoplasm Transplantation

KW - Purines

KW - Receptor, erbB-2

U2 - 10.1158/1078-0432.CCR-07-4633

DO - 10.1158/1078-0432.CCR-07-4633

M3 - Article

C2 - 18594016

SN - 1078-0432

VL - 14

SP - 4326

EP - 4335

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13

ER -

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Abstract

Keywords

Access to Document

Fingerprint

Cite this